How Do Ozempic, Mounjaro & Other GLP-1 Agonists Work? Dr. Zachary Knight & Dr. Andrew Huberman

Neuroscience Meets GLP-1: A Deep Conversation Worth Your Time

When Andrew Huberman sits down with Dr. Zachary Knight, a neuroscientist at UCSF who studies how the brain regulates hunger and body weight, the conversation goes places that most GLP-1 content never reaches. This clip from the Huberman Lab podcast has pulled in nearly 185,000 views, and it stands out because it focuses on the brain side of the equation rather than the metabolic side that most explainers cover.

The central question Dr. Knight addresses is straightforward: how do drugs like Ozempic and Mounjaro actually change the way your brain processes hunger signals? The answer turns out to be more nuanced than "they make you feel full." Knight explains that GLP-1 receptors exist throughout the brain, including in areas involved in reward processing, more than appetite regulation. This means these drugs are not simply turning off a hunger switch. They are changing how your brain evaluates food, how much pleasure you derive from eating, and potentially how you respond to other rewarding stimuli.

This is the kind of conversation that reframes your entire understanding of what these medications do. Most people think of Ozempic as a drug that makes you less hungry. Knight's research suggests it is more accurate to say it changes your relationship with food at a neurological level. That distinction matters for understanding both the benefits and the potential long-term implications of these drugs.

How Your Brain Actually Controls Hunger

Knight's lab has done some of the most detailed work mapping hunger circuits in the brain. In this clip, he explains a few key concepts that are worth understanding. First, there are neurons in the hypothalamus (specifically AgRP neurons) that drive the feeling of hunger. When these neurons are active, you feel hungry. When they are suppressed, you do not. GLP-1 drugs appear to suppress these neurons, which is one mechanism by which they reduce appetite.

But the story does not stop there. Knight explains that hunger is about more than a single circuit. There are multiple parallel systems involved, including reward circuits in the mesolimbic dopamine system. When you eat something tasty, dopamine neurons fire and reinforce the behavior. GLP-1 receptors are present in these reward areas too, which may explain why people on these medications often report more than eating less, but caring less about food. The emotional pull toward food seems to diminish alongside the physical hunger.

Huberman asks good follow-up questions about whether this effect on reward circuits might explain the early reports of GLP-1 drugs reducing alcohol consumption and other addictive behaviors. Knight is appropriately careful in his response, noting that the research is early and mostly observational at this point, but the biological plausibility is there. If GLP-1 receptors modulate reward processing broadly, for more than food, then effects on other cravings would make sense mechanistically.

What the Conversation Gets Right

The biggest strength here is the depth and specificity of the neuroscience. Knight is not speculating or extrapolating from press releases. He is describing his own lab's work and the broader body of research on hypothalamic and brainstem circuits that regulate feeding. The discussion of AgRP neurons, POMC neurons, and the nucleus of the solitary tract is done at a level that is technical enough to be meaningful but still accessible to a lay audience. Huberman deserves credit for asking questions that push Knight to explain mechanisms rather than just outcomes.

The conversation also handles uncertainty well. When they discuss the effects of GLP-1 drugs on alcohol and nicotine cravings, both speakers acknowledge that the evidence is preliminary. They explain why the hypothesis is biologically plausible without claiming it is proven. This is how responsible science communication should work, and it is refreshing compared to the hype cycles that surround these drugs in mainstream media.

What It Misses

This clip is pulled from a longer podcast episode, and the editing means some context is lost. The conversation focuses almost entirely on mechanism and does not address practical questions like dosing, side effects, or how to get started on these medications. If you are looking for actionable information you can bring to a doctor's appointment, this video will not give you that directly. It is more of a "understand the science deeply" resource than a "here is what to do" resource.

The discussion also does not touch on the differences between specific GLP-1 drugs. Mounjaro (tirzepatide) is mentioned in the title but the conversation treats all GLP-1 agonists fairly similarly. The fact that tirzepatide is a dual GLP-1/GIP agonist with a distinct mechanism gets minimal attention. For patients trying to understand why their doctor chose one drug over another, this gap matters.

Questions to Bring to Your Doctor

After watching this, you are going to have a more sophisticated understanding of the brain effects of GLP-1 drugs than most patients. Use it well:

Ask your doctor about the neurological effects you should expect. Will your experience of hunger change gradually or suddenly? Will cravings for specific foods shift? Knowing what to expect can help you track whether the medication is working as intended.

If you are someone who uses food for emotional regulation, stress relief, or comfort, ask about support strategies. The brain's reward system is being altered by these medications, and for some people that shift can feel disorienting or even produce low mood. Having a plan for that emotional adjustment is smart.

Ask about what current research says regarding GLP-1 effects on alcohol or nicotine use if those are relevant to your life. Your doctor may not have the latest data, but the question opens a useful conversation about monitoring for changes in those behaviors.

Ask about long-term brain effects. What do we know about what happens to hunger circuits after someone stops taking a GLP-1 drug? Knight's research suggests that the neurons that drive hunger are still there and still functional. Understanding this helps set realistic expectations for what maintenance might look like.

Who Should Watch This

This is for anyone who wants to understand GLP-1 drugs at a deeper level than "they reduce appetite." If you are interested in neuroscience, if you want to understand why these drugs feel different from other weight loss approaches, or if you are trying to make sense of reports about GLP-1 effects beyond weight loss, this conversation is exactly what you need. It rewards attention and repeat viewing. Just know that it is science-focused, not patient-guidance-focused. You will leave smarter but you will still need other resources for the practical side of starting, managing, or stopping these medications.

One of the more thought-provoking moments in the conversation deals with what Knight calls the "defended body weight" concept. His research suggests that the brain actively defends a particular body weight set point through complex neuronal circuits, and that this defense mechanism is one reason why diet-based weight loss is so difficult to maintain long-term. GLP-1 drugs appear to lower this defended set point, at least while the medication is active, which is why patients often describe their relationship with food as fundamentally different rather than just feeling less hungry. This framework has real implications for understanding why weight regain after stopping these drugs is so common and so rapid.

The conversation also touches on the difference between homeostatic hunger (the biological need for calories) and hedonic hunger (the desire to eat for pleasure). Knight's work suggests that GLP-1 drugs affect both systems, but potentially through different brain circuits. This dual effect may explain why some patients report more than eating less but genuinely losing interest in foods they previously found irresistible. The reduction in hedonic eating, the kind driven by reward rather than caloric need, is one of the more remarkable subjective experiences that GLP-1 patients describe, and Knight provides a neurological framework for understanding why it happens.

For listeners who want to go deeper, this clip is worth treating as a gateway to Knight's published research and his longer appearances on other podcasts where the conversation has room to develop more fully. The neuroscience of appetite regulation is one of the most active and exciting areas of metabolic research right now, and Knight's lab is at the center of it. Understanding the brain side of GLP-1 drugs adds a dimension to your knowledge that pure pharmacology cannot provide, and it may change how you think about your own experience with these medications in meaningful ways.

Knight's research also provides context for why individual responses to GLP-1 drugs vary so dramatically. If the brain circuits mediating appetite and reward are not identical across individuals, which they almost certainly are not given genetic and developmental variation, then the same drug dose could produce very different subjective experiences in different people. This may be why some patients describe a complete transformation in their relationship with food while others experience only modest appetite reduction. The neuroscience suggests this variation is biological rather than psychological, which is a useful reframe for patients who feel like the medication is not working as well for them as for others they see online.

For anyone interested in the future direction of this research, Knight mentions ongoing work on mapping the specific neuronal populations involved in different aspects of feeding behavior, from hunger initiation to meal termination to food preference. As this mapping becomes more complete, it may eventually enable more targeted interventions that can modulate specific aspects of eating behavior rather than the broad-spectrum approach that current GLP-1 drugs take. This is years away from clinical application, but it represents the frontier of the field and gives context for why the current drugs, as effective as they are, may be just early tools in a much more precise toolkit that is still being developed.